.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,498,600

« Back to Dashboard

Details for Patent: 5,498,600

Title: Biologically active mosaic proteins
Abstract:Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the proteins may have two polypeptide chains, one of the chains being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, the second of the chains being substantially homologous to either the A-chain or the B-chain of PDGF, the proteins being chemotactic or mitogenic for fibroblasts. Alternatively, each of the two polypeptide chains may be a mosaic of amino acid sequences as described above. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm-blooded animals are also disclosed.
Inventor(s): Murray; Mark J. (Seattle, WA), Kelly; James D. (Seattle, WA)
Assignee: ZymoGenetics, Inc. (Seattle, WA)
Filing Date:Oct 07, 1994
Application Number:08/319,776
Claims:1. A recombinant protein having first and second non-identical polypeptide chains, said first chain being substantially identical to either the A- or B-chain of PDGF (platelet-derived growth factor) and being a mosaic of amimo acid sequences substantially identical to portions of the A- and B-chains of PDGF, said second chain being substantially identical to the A-chain of PDGF, wherein each of said chains includes a substitution of one or more of the cysteine residues corresponding to residues 37, 43, 46 or 47 of the PDGF A-chain, wherein said chains are disulfide bonded together, and wherein said first chain differs from the A- and B-chains of PDGF in at least one amino acid residue substitution, said protein being chemotactic or mitogenic for fibroblasts.

2. The protein of claim 1 wherein said polypeptide chains are substantially identical to one another.

3. The protein of claim 1 wherein said second chain is substantially identical to the A-chain of PDGF from amino acid 15 to amino acid 104.

4. The protein of claim 1 wherein said second chain is substantially identical to the A-chain of PDGF from amino acid 23 to amino acid 104.

5. The protein of claim 1 wherein said second chain is substantially identical to the A-chain of PDGF from amino acid 9 to amino acid 95.

6. The protein of claim 1 wherein said second chain is substantially identical to the A-chain of PDGF from amino acid 23 to amino acid 95.

7. The protein of claim 1 wherein said second chain is substantially identical to the A-chain of PDGF from amino acid 1 to amino acid 95.

8. The protein of claim 1 wherein said second chain is substantially identical to the amino acid sequence of FIG. 9, from A-chain amino acid 1 to amino acid 104.

9. The protein of claim 1 wherein said mosaic chain is substantially identical to A-chain amino acids 1-17 fused in reading frame to B-chain amino acids 24-109.

10. The protein of claim 1 wherein said mosaic chain is substantially identical to A-chain amino acids 1-17 fused in reading frame to B-chain amino acids 24-97 fused in reading frame to A-chain amino acids 92-104.

11. A recombinant protein having first and second non-identical polypeptide chains, said first chain being substantially identical to either the A- or B-chains of PDGF and being a mosaic of amino acid sequences substantially identical to portions of the A- and B-chains of PDGF, wherein each of said chains includes a substitution of one or more of the Cysteine residues corresponding to residues 37, 43, 46 or 47 of the PDGF A-chain, wherein said chains are disulfide bonded together, and wherein said first chain differs from the A- and B-chains of PDGF in at least one amino acid residue substitution, said protein being chemotactic or mitogenic for fibroblasts.

12. The protein of claim 11 wherein said polypeptide chains are substantially identical to one another.

13. The protein of claim 11 wherein said second chain is substantially identical to the B-chain of PDGF from amino acid 15 to amino acid 109.

14. The protein of claim 11 wherein said second chain is substantially identical to the B-chain of PDGF from amino acid 29 to amino acid 109.

15. The protein of claim 11 wherein said second chain is substantially identical to the B-chain of PDGF from amino acid 15 to amino acid 101.

16. The protein of claim 11 wherein said second chain is substantially identical to the B-chain of PDGF from acid 29 to amino acid 101.

17. The protein of claim 11 wherein said second chains are substantially identical to the B-chain of PDGF from amino acid 1 to amino acid 101.

18. The protein of claim 11 wherein said second chain is substantially identical to the amino acid sequence of FIG. 9, from B-chain amino acid 1 to amino acid 109.

19. The protein of claim 11 wherein said mosaic chain is substantially identical to A-chain amino acids 1-17 fused in reading frame to B-chain amino acids 24-109.

20. The protein of claim 11 wherein said mosaic chain is substantially identical to A-chain amino acids 1-17 fused in reading frame to B-chain amino acids 24-97 fused in reading frame to A-chain amino acids 92-104.

21. A recombinant protein having first and second non-identical polypeptide chains, each of said chains being substantially identical to either the A- or B-chains of PDGF and being a mosaic of amino acid sequences substantially identical to portions of the A- and B-chains of PDGF, wherein each of said chains includes a substitution of one or more of the cysteine residues corresponding to residues 37, 43, 46 or 47 of the PDGF A-chain, wherein said chains are disulfide bonded together, and wherein each of said chains differs from the A- and B-chains of PDGF in at least one amino acid residue substitution, said protein being chemotactic or mitogenic for fibroblasts.

22. The protein of claim 21 wherein said polypeptide chains are substantially identical to one another.

23. A therapeutic composition comprising a recombinant protein having first and second polypeptide chains, one of said chains being substantially identical to either the A- or B-chains of PDGF and being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, the second of said chains being substantially identical to the A-chain of PDGF, and a physiologically acceptable carrier or diluent.

24. The therapeutic composition of claim 23 wherein said carrier or diluent is selected from the group consisting of albumin, sterile water, and saline.

25. The therapeutic composition of claim 23, including an adjuvant.

26. The therapeutic composition of claim 25 wherein said adjuvant is selected from the group consisting of collagen, hyaluronic acid, fibronectin-, factor XIII, and an antibiotic.

27. The therapeutic composition of claim 23 wherein said protein is present in a concentration of from about 1 to 50 micrograms per milliliter of total volume.

28. A therapeutic composition comprising a recombinant protein having first and second polypeptide chains, one of said chains being substantially identical to either the A- or B-chains of PDGF and being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, the second of said chains being substantially identical to the B-chain of PDGF, and a physiologically acceptable carrier or diluent.

29. The therapeutic composition of claim 28 wherein said carrier or diluent is selected from the group consisting of albumin, sterile water, and saline.

30. The therapeutic composition of claim 28, including an adjuvant.

31. The therapeutic composition of claim 30 wherein said adjuvant is selected from the group consisting of collagen, hyaluronic acid, fibronectin, factor XIII, and an antibiotic.

32. The therapeutic composition of claim 28 wherein said protein is present in a concentration of from about 1 to 50 ug/ml of total volume.

33. A therapeutic composition comprising a recombinant protein having first and second polypeptide chains, one of said chains being substantially identical to either the A- or B-chains of PDGF and being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, the second of said chains being substantially identical to the A-chain of PDGF, and a physiologically acceptable carrier or diluent.

34. The therapeutic composition of claim 33 wherein said carrier or diluent is selected from the group consisting of albumin, sterile water, and saline.

35. The therapeutic composition of claim 33, including an adjuvant.

36. The therapeutic composition of claim 35 wherein said adjuvant is selected from the group consisting of collagen, hyaluronic acid, fibronectin, factor XIII, and an antibiotic.

37. The therapeutic composition of claim 33 wherein said protein is present in a concentration of from about 1 to 50 ug/ml of total volume.

38. A method for enhancing the wound-healing process in warm-blooded animals, comprising administering to the animal an amount effective to enhance the wound-healing process of a substantially pure recombinant protein having two polypeptide chains, one of said chains being substantially identical to either the A- or B-chains of PDGF and being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, the second of said chains being substantially identical to the A-chain of PDGF, and a physiologically acceptable carrier or diluent.

39. A method for enhancing the wound-healing process in warm-blooded animals, comprising administering to the animal an amount effective to enhance the wound-healing process of a substantially pure recombinant protein having two polypeptide chains, one of said chains being substantially identical to either the A- or B-chains of PDGF and being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, the second of said chains being substantially identical to the B-chain of PDGF, and a physiologically acceptable carrier or diluent.

40. A method for enhancing the wound-healing process in warm-blooded animals, comprising administering to the animal an amount effective to enhance the wound-healing process of a substantially pure recombinant protein having two polypeptide chains, each of said chains being substantially identical to either the A- or B-chains of PDGF and being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, said protein being chemotactic or mitogenic for fibroblasts, and a physiologically acceptable carrier or diluent.

41. A recombinant protein having two identical polypeptide chains, each of said chains being substantially identical to either the A- or B- chains of PDGF and being a mosaic of amino acid sequences substantially identical to portions of the A- and B-chains of PDGF, wherein each of said chains includes a substitution of one or more of the cysteine residues corresponding to residues 37, 43, 46 or 47 of the PDGF A-chain, wherein said chains are disulfide bonded together, and wherein each of said chains differs from the A- and B-chains of PDGF in at least one amino acid residue substitution, said protein being chemotactic or mitogenic for fibroblasts.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc